Loading
Life sciences · Journal article
Discover Oncology · November 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
N6-methyladenosine (m6A) is a reversible and context-dependent RNA modification that links transcript processing to bladder cancer growth, immune escape, treatment response, and tumor-cell plasticity. This review asks three questions: which m6A mechanisms have been experimentally resolved in bladder cancer; how CRISPR systems can establish causal relationships at regulator, transcript, and nucleotide levels; and which targets are sufficiently supported for translational development. We report the experimental settings represented for each axis and assess mechanistic resolution separately; cross-cancer observations are retained only as hypotheses for bladder cancer. Bladder-cancer evidence identifies oncogenic METTL3-centered axes involving AFF4-NF-kB-MYC, ITGA6, pri-miR-221/222-PTEN, RPN2, and PD-L1; an FTO-MALAT1-miR-384-MAL2 axis; YTHDF2-dependent degradation of DDX58/RIG-I; WTAP-NRF2 regulation; and IGF2BP3-mediated stabilization of HMGB1. Reader-resolved axes include METTL3-ITGA6-YTHDF1/3, WTAP-NRF2-YTHDF1, FTO-MALAT1-YTHDF2, YTHDF2-DDX58, IGF2BP3-HSP90AB1, and IGF2BP3-CDK6; METTL3-RPN2-YTHDF1 and METTL3-PD-L1-IGF2BP1 remain reader-implicated because direct reader-target binding was not demonstrated, and RPN2 additionally lacks experimental target-specific m6A mapping. IGF2BP3-HMGB1, YTHDC1-HECW1 and IGF2BP3-PPARγ also remain reader-implicated, with m6A dependence unestablished for HMGB1 and HECW1. No axis has achieved site-resolved validation with site-mutant phenotypic rescue in an immune-competent orthotopic model. METTL14 findings remain directionally inconsistent. Cas9/Cas12a DNA editing, active Cas13 RNA knockdown, and inactive RNA-targeting Cas platforms carrying m6A effectors are treated as distinct technologies. Two bladder-cancer proof-of-concept studies used guide-directed m6A editing: RCas9-METTL3 targeted CDCP1, and a multisite dCasRx-METTL3/ALKBH5 platform targeted ITGA6. These experiments support causal research applications but do not constitute an established therapy. We propose a controlled workflow integrating m6A mapping, genetic perturbation, site-mutant rescue, reader identification, organoids, in vivo models, and therapy-response assays. Detection, biomarker development, pharmacology, delivery, and safety are evaluated with emphasis on analytical validity and the absence of clinical validation for m6A-directed treatment in bladder cancer.